Fig. 1

Network plots of treatments for PFS and adverse events. A PFS in the overall population with ovarian cancer, B PFS of women with a BRCAm, C PFS of women with HRD, and D Adverse events in all populations. The size of the three nodes (treatments) increased with the number of studies included in the corresponding nodes, and lines connecting two nodes were thickened with larger number of studies comparing the two treatments [24]. BRCAm, BRCA1/2 mutation; HRD, homologous recombination deficiency